These limitations underscore the need for biologically targeted approaches, highlighted by the recent accelerated approval of tarlatamab for post-platinum, post-immunotherapy disease and the growing interest in DLL3-, TROP2-, and B7-H3-directed therapies as more rational strategies for relapsed ES-SCLC. This evidence concerns the gene DLL3 and small cell lung carcinoma.